On the basis of animal models of arterial injury, smooth muscle cell proliferation has been posited as a dominant event in restenosis. Unfortunately, little is known about this proliferation in the human restenotic lesion. The purpose of this study was to determine the extent and time course of proliferation in primary and restenotic coronary atherectomy-derived tissue. Primary (n= 118) and restenotic (n= 100) coronary atherectomy specimens were obtained from 211 nonconsecutive patients. Immunocytochemistry for the proliferating cell nuclear antigen (PCNA) was used to gauge proliferation in the atherectomy specimens. The identity of PCNA-positive cells was then determined using immunohistochemical cell-specific markers. Eighty-two percent of primary specimens and 74% of restenotic specimens had no evidence of PCNA labeling. The majority of the remaining specimens had only a modest number of PCNA-positive cells per slide (typically <50 cells per slide). In the restenotic specimens, PCNA labeling was detected over a wide time interval after the initial procedure (eg, 1 to 390 days), with no obvious proliferative peak. Cell-specific immunohistochemical markers identified primary and restenotic PCNApositive cells as smooth muscle cells, macrophages, and endothelial cells. In conclusion, the findings were as follows: (1) end points that measure only loss of lumen diameter.6,7 The limited utility of animal models suggests either that the biology of restenosis is very different in animals compared with human atherosclerotic vessels or that restenosis is due to processes other than the intimal hyperplasia that is usually studied in animal models.
T he therapeutic potential of interventional cardiology is limited by the high proportion of patients who develop postprocedural restenosis. The mechanisms leading to restenosis remain unclear. Arterial recoil, accelerated progression of the underlying atherosclerotic lesion, overproduction of extracellular matrix, thrombus formation, and smooth muscle cell proliferation have been proposed as the critical processes leading to restenosis.' Intimal hyperplasia due to smooth muscle cell proliferation is most commonly cited as the dominant cellular event in the restenotic process.2-5 Drugs that inhibit smooth muscle cell hyperplasia following angioplasty in experimental animals have been administered to patients with the hope of preventing restenosis. Although in some clinical trials the dose of the study drug differed from that used in the animal experiments, to date all drugs that have been clinically tested appear to be unsuccessful in preventing restenosis, at least according to angiographic end points that measure only loss of lumen diameter. 6, 7 The limited utility of animal models suggests either that the biology of restenosis is very different in animals compared with human atherosclerotic vessels or that restenosis is due to processes other than the intimal hyperplasia that is usually studied in animal models.
The most extensively studied animal model involves balloon injury to the rat carotid artery. 8 The kinetics of this model are very well characterized. Unlike a human coronary artery, the normal rat carotid artery lacks the innermost arterial layer or intima. Within the first 48 to 72 hours following balloon angioplasty, there is a wave of smooth muscle cell proliferation involving from 10% to over 50% of the medial smooth muscle cells. Medial proliferation is followed by the migration of smooth muscle cells across the internal elastic lamina and formation of a neointima over the next few days. Initially, most of the neointimal cells are replicating. Intimal replication declines over a period of days and weeks, although the neointima remains hyperproliferative, at least in response to the infusion of angiotensin II.9 Therefore, unlike primary coronary artery lesions that have a near-occlusive neointimal mass, these rat experiments serve as a model for the initial formation of an intima. This process, the formation of a neointima, may or may not be relevant to the processes leading to restenosis in a vessel that already has an atherosclerotic intima. (Fig 1) . Double-label immunocytochemistry. If PCNA-positive cells could be identified on an atherectomy tissue slide by light microscopy at x 400 magnification, adjacent tissue sections from the same block were then prepared for double labeling with PCNA and a cell type-specific antibody. Briefly, the single-label procedure was performed as described above, with 3,3'-diaminobenzidine and nickel chloride being added to yield a black reaction product. After washing, sections were incubated with the second primary antibody or lectin overnight. Specifically, these reagents included the following: antismooth muscle a-actin (1: 500 dilution, Boehringer Mannheim Corp, Indianapolis, Ind) to identify smooth muscle cells, anti-CD-68 (DAKO-CD-68, KP1, 1:500 dilution, DAKO) to identify macrophages, and the lectin Ulex europaeus agglutinin I (1:500 dilution, Vector Laboratories) to identify endothelial cells. This was followed by sequentially incubating with biotinylated anti-mouse IgG or anti-Ulex IgG (Vector) and an avidin-biotin-alkaline phosphatase complex (Vector). The alkaline phosphatase was then developed with the standard ABC substrate kit (Vector) to yield a red reaction product and then counterstained with methyl green.
Cell Counting
The total number of PCNA-positive cells per slide was counted at x 400 light magnification with the investigator blinded to the clinical details pertaining to the specimens. The total numbers of nuclei present on 18 PCNA-positive and 19 PCNA-negative atherectomy slides were counted using a computerized image analysis system (BioScan Optimus, BioScan, Inc, Edmonds, Wash). that included 10 or more PCNA-positive nuclei was counted manually to determine both the total number of PCNA-positive nuclei per fragment and the number of cells that labeled for PCNA and for a specific cell identity marker. The ratio of the total number of double-labeled cells to total number of PCNA-labeled nuclei was used to indicate the percentage of either macrophages, smooth muscle cells, or endothelial cells that were proliferating in each fragment.
Statistical Methods
All data are reported as mean--SD. The total numbers of cells on the primary and restenotic slides that were counted were compared by Student's t test. The frequencies of PCNA-positive cells in the primary and restenotic groups were compared by k test. To determine if the number of PCNA-positive cells in a specimen varied with the time interval after the initial coronary interventional procedure, the specimens were ranked according to four arbitrary time periods, and Spearman's rank correlation coefficient was computed. Results 
PCNA Labeling
The vast majority of atherectomy specimens from either primary or restenotic lesions showed no evidence of PCNA-labeled cells (Fig 2) . Because the frequency was low, 26% of the restenotic specimens had some PCNA labeling detected over a wide time interval after the initial procedure (eg, 1 to 390 days) (Fig 3) . On the basis of the mean number of nuclei per slide, the vast majority of these specimens had <1% of all cells labeled PCNA-positive. Because of possible relevance to the kinetics of the response seen in the rat, we focused particular attention on the proliferative profile of restenotic specimens collected within 2 months of a previous interventional coronary procedure. Only 12 of 30 specimens obtained within 60 days of the initial coronary interventional procedure had one or more PCNA-positive nuclei per slide. There was no difference in the proliferative profile of restenotic specimens collected in the first 3 months, 4 to 6 months, 7 to 9 months, or >9 months after the initial interventional procedure (Spearman's rank correlation coefficient, 0.081; P=0.43). Furthermore, PCNA labeling was found to be low, independent of whether the initial procedure was a percutaneous transluminal coronary angioplasty or a directional coronary atherectomy. We considered the possibility that the absence of a replicative index akin to the rat carotid artery model might be due to a redistribution of mass with angioplasty compared with a more extensive injury associated with the cutting action of atherectomy. However, on examining the PCNA index of nine specimens collected from patients within 6 days of the initial procedure (five atherectomies and four angioplasties), all postatherectomy specimens were devoid of PCNA labeling, and three of the postangioplasty specimens were PCNA-positive with 1, 7, and 20 PCNA-positive cells per slide each.
Identity of PCNA-Positive Nuclei PCNA-positive smooth muscle cells, macrophages, and endothelial cells were identified in both primary and restenotic specimens (Fig 4) . Since the typical atherectomy slide contains several tissue fragments, we focused our attention on the relative abundance and distribution of these cells in fragments with more than 10 PCNA-positive nuclei. Most PCNA-positive slides had at least one or two fragments with 10 or more PCNA-positive cells. However, because of the small size of many of the original atherectomy tissue blocks, it proved difficult to obtain three representative adjacent sections for double labeling for all PCNA-positive specimens. In some instances, tissue fragments were torn with sectioning; other specimens were so thin that serial sections did not Since humans cannot readily be labeled with tritiated thymidine or bromodeoxyuridine, our ability to assess cell replication depends on the use of a technique that identifies replicating cells by the characteristic presence of a cell cycle-specific antigen. PCNA is a highly conserved auxiliary protein of mammalian DNA polymerase-S that is synthesized in the S phase of the cell cycle but may also be present in G, and G2 phases.14,15
The regulation of PCNA expression is complex, with both transcriptional and posttranscriptional levels of involvement. 16 Furthermore, the regulation of PCNA expression in quiescent cells differs from that in contin- 29 In addition, there is circumstantial evidence from one right coronary atherectomy specimen not reported in this study that our PCNA labeling methodology was appropriate. This specimen was not included in this study because it contained a mixture of tissue from a lesion that had been atherectomized 18 days previously, as well as a de novo more distal lesion that probably arose from arterial trauma with the initial more proximal atherectomy, and had 198 PCNA-positive cells out of a total of 10 049 cells (1.9%). This percentage is higher than for all other specimens reported in the study and may represent the consequences of arterial trauma to a relatively disease-free segment of artery-a response somewhat analogous to the more robust proliferation observed in the rat carotid artery balloon model. Finally, one criticism of PCNA labeling relative to other proliferative measurements is that it is likely to be oversensitive in detecting proliferative cells, since PCNA is expressed through a broader period of cell cycle traverse.13 Therefore, if anti-PCNA antibodies are overlabeling proliferating cells, the degree of proliferation in these atherectomy specimens may actually be lower than the already minimal levels that we have measured.
The low level of PCNA labeling seen in the primary coronary artery lesions is not surprising. Gordon (Fig 5) .
Apart from questions about the absolute levels of replication as measured by PCNA labeling, it is very important to point out that our data do not support the hypothesis that replication in restenotic tissue is any higher than the levels seen in the original plaque. PCNA the average total number of cells per slide was found to be approximatelv 4600. Therefore, the majoritv of slides had 1.0% or fewer cells that were PCNA-positive. For all PCNA-positive slides studied, there was no difference in the relative abundance of specific PCNApositive cell tvpes in primary compared with restenotic specimens.
Our failure to find a time course of replication similar to that seen in the rat requires that we consider possible sources of error in our human studies. Tissue sample selection bias is a major concern. The depth of 'vessel wall that is cut and the amount of tissue recovered have an obvious influence on the conclusions that can be drawn about the lesion. Typically, the interventional cardiologist cuts the lesion in all four quadrants of the vessel circumference (even for some eccentric lesions). According to the practices of the cardiologists who contributed atherectomy specimens to this study, as much plaque as possible was removed until the lesion looked suitably "debulked." In fact, it is likely that atherectomy removes preexisting atherosclerotic plaque, any "new" restenotic mass (if it exists), and the lesion margins. Therefore, given the potential heterogeneity of the specimens, we have included an extensive number to look for trends and to reduce any background or spurious results. Alternatively, one might argue that cellular proliferation does occur after the initial procedure but only in the relatively less accessible media or adventitia. Although this is possible, it is important to note that coronary atherectomy removes portions of adventitia in as many as 30% of procedures and therefore should pick up deeper proliferative pockets in the vessel wall.37 Finally, our data do not rule out a potential role for proliferation in the early time interval after the initial procedure. Of nine specimens collected within 6 days of the initial procedure, only three had evidence of PCNA labeling with 1, 7, and 20 PCNA-positive cells, respectively. (Although not reported in this study because of differences in fixation, we have also examined five formalin-fixed specimens collected within 13 days of the initial procedure and found two with evidence of PCNA labeling.) Therefore, we may simply lack enough specimens in this period to demonstrate a brief proliferative spike.
If the kinetics of neointimal formation in the rat are a poor model for the sequence of events seen in humans, what then are the key events that lead to postprocedural luminal narrowing? First, these data do not rule out a major role for replication, although it may occur at a low level. Typically, restenosis occurs 3 to 6 months after the primary procedure -a time interval long enough for indolent cell replication to produce a considerable cell mass. Even if primary and restenotic lesions have similar replication rates, differences in rates of cell death could accelerate growth of the restenotic tissue. Second, it is possible that the restenotic tissue specimens represent an acceleration of the normal atherosclerotic process. This may involve more of an alteration in gene expression than a predominantly proliferative response and may be particularly relevant to those plaque regions characterized by nearhomogenous collections of stellate-shaped smooth muscle cells surrounded by abundant extracellular matrix. The sequence of events that results in the production of this space occupying matrix might be key to understanding lesion progression. Finally, it may be useful to liken an atherectomy to wound debridement. The wound response, including the forces generating wound contraction, occurs at the edges of the wound and may play an important role in the stenosis of the vessel wall.
In summary, PCNA labeling of primary and restenotic human coronary atherectomy specimens indicates that proliferation occurs infrequently and at low levels. These findings may help explain why antiproliferative therapies have not been effective in retarding the progression of primary lesions or preventing restenosis from occurring.67,38 Future study of the events that result in lesion progression will require careful evaluation of the role of various molecules in lesions, not only for mitogenic potential but also for control of smooth muscle cell migration and matrix production, angiogenesis, thrombosis, and vasoconstriction. Animal models will require the production of primary lesions that resemble those of humans before meaningful therapeutic experiments can be conducted in the field of restenosis research.
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